Literature DB >> 1372448

Induction of broadly cross-reactive cytotoxic T cells recognizing an HIV-1 envelope determinant.

H Takahashi1, Y Nakagawa, C D Pendleton, R A Houghten, K Yokomuro, R N Germain, J A Berzofsky.   

Abstract

An immunodominant determinant for cytotoxic T lymphocytes (CTLs) exists in the hypervariable portion of human immunodeficiency virus-1 (HIV-1) gp160. Three mouse CTL lines (specific for isolates MN, RF, and IIIB) were examined for recognition of homologous determinants from distinct isolates. Only MN-elicited CTLs showed extensive interisolate cross-reactivity. Residue 325 played a critical role in specificity, with MN-elicited CTLs responding to peptides with an aromatic or cyclic residue and IIIB-induced cells recognizing peptides with an aliphatic residue at this position. CTL populations with broad specificities were generated by restimulation of IIIB-gp160 primed cells with MN-type peptides that have an aliphatic substitution at 325. This represents an approach to synthetic vaccines that can generate broadly cross-reactive CTLs capable of effector function against a wide range of HIV isolates.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1372448     DOI: 10.1126/science.1372448

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  47 in total

1.  A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.

Authors:  F Verrier; S Burda; R Belshe; A M Duliege; J L Excler; M Klein; S Zolla-Pazner
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Subsets of memory cytotoxic T lymphocytes elicited by vaccination influence the efficiency of secondary expansion in vivo.

Authors:  Michael S Seaman; Fred W Peyerl; Shawn S Jackson; Michelle A Lifton; Darci A Gorgone; Jörn E Schmitz; Norman L Letvin
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

3.  Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines.

Authors:  Dan H Barouch; Paul F McKay; Shawn M Sumida; Sampa Santra; Shawn S Jackson; Darci A Gorgone; Michelle A Lifton; Bimal K Chakrabarti; Ling Xu; Gary J Nabel; Norman L Letvin
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

4.  Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors.

Authors:  Shawn M Sumida; Diana M Truitt; Michael G Kishko; Janelle C Arthur; Shawn S Jackson; Darci A Gorgone; Michelle A Lifton; Wouter Koudstaal; Maria G Pau; Stefan Kostense; Menzo J E Havenga; Jaap Goudsmit; Norman L Letvin; Dan H Barouch
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

5.  Efficient generation of mucosal and systemic antigen-specific CD8+ T-cell responses following pulmonary DNA immunization.

Authors:  Maytal Bivas-Benita; Liat Bar; Geoffrey O Gillard; David R Kaufman; Nathaniel L Simmons; Avi-Hai Hovav; Norman L Letvin
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

6.  Molecular analysis of TCR and peptide/MHC interaction using P18-I10-derived peptides with a single D-amino acid substitution.

Authors:  Yohko Nakagawa; Hiroto Kikuchi; Hidemi Takahashi
Journal:  Biophys J       Date:  2007-01-05       Impact factor: 4.033

7.  Generation of CD8+ T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env.

Authors:  Mark J Cayabyab; Avi-Hai Hovav; Tsungda Hsu; Georgia R Krivulka; Michelle A Lifton; Darci A Gorgone; Glenn J Fennelly; Barton F Haynes; William R Jacobs; Norman L Letvin
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

8.  Duration of antigen expression in vivo following DNA immunization modifies the magnitude, contraction, and secondary responses of CD8+ T lymphocytes.

Authors:  Avi-Hai Hovav; Michael W Panas; Shaila Rahman; Piya Sircar; Geoffrey Gillard; Mark J Cayabyab; Norman L Letvin
Journal:  J Immunol       Date:  2007-11-15       Impact factor: 5.422

Review 9.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

10.  Cross-reactive lysis of human targets infected with prototypic and clinical human immunodeficiency virus type 1 (HIV-1) strains by murine anti-HIV-1 IIIB env-specific cytotoxic T lymphocytes.

Authors:  S Chada; C E DeJesus; K Townsend; W T Lee; L Laube; D J Jolly; S M Chang; J F Warner
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.